Christopher Ryan Sullivan, Chief Financial Officer at Avalo Therapeutics, Inc. (AVTX), sold 10,185 shares at $17.62 ($179K) on 2026-09-10, disclosed to the SEC on 2026-09-11.
Scheduled sale ($179k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| AVTX | SELL | 2026-05-11 | $449K | — | Filing → |
| AVTX | SELL | 2026-05-07 | $949K | — | Filing → |
| AVTX | SELL | 2026-05-01 | $223K | — | Filing → |